Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat

References

• Aksenova MV, Silvers JM, Akenov MY, Nath A, Ray PD, Mactutus CF, Booze RM (2006). HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395:235–239.
   PubMed Web of Science ®Google Scholar
• Albert KA, Helmer-Matyjek E, Nairn AC, Müller TH, Haycock JW, Greene LA, Goldstein M, Greengard P (1984). Calcium/phospholipid-dependent protein kinase (protein kinase C) phosphorylates and activates tyrosine hydroxylase. Proc Natl Acad Sci U S A 81:7713–7717.
   PubMed Web of Science ®Google Scholar
• Biadgilign S, Deribew A, Amberbir A, Deribe K (2008). Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. E-Pub BMC Pediatr 8:53.
   PubMed Web of Science ®Google Scholar
• Campbell DG, Hardie DG, Vulliet PR (1986). Identification of four phosphorylation sites in the N-terminal region of tyrosine hydroxylase. J Biol Chem 261:10489–10492.
   Google Scholar
• Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF (1992). Site-directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP dependent phosphorylation on enzyme activity. J Biol Chem 267:12639–12646.
   Google Scholar
• Ferris MJ, Mactutus CF, Booze RM (2008). Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in neuroAIDS. Neurosci Biobehav Rev 32:883–909.
   Google Scholar
• Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009a). The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159: 1292–1299.
   Google Scholar
• Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009b). In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 63: 181–185.
   Google Scholar
• Fitting S, Booze RM, Mactutus CF (2006). Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response. Int J Dev Neurosci 24:275–283.
   Google Scholar
• Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006). Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1:410–20.
   Google Scholar
• Havens JF, Whitaker AH, Feldman JF, Ehrhardt AA (1994). Psychiatric morbidity in school-age children with congenital human immunodeficiency virus infection: a pilot study. J Dev Behav Pediatr 15:S18–25.
   PubMed Web of Science ®Google Scholar
• Kieburtz KD, Epstein LG, Gelbard HA, Greenamyre JT (1991). Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex. Therapeutic implications. Arch Neurol 48:1281–4.
   PubMedGoogle Scholar
• Lashomb A, Vigorito M, Chang SL (2009). Further characterization of the spatial learning deficit in the human immunodeficiency virus-1 transgenic rat. J NeuroVirol 15:14–24.
   Web of Science ®Google Scholar
• Lopez OL, Smith G, Meltzer CC, Becker JT (1999). Dopamine systems in human immunodeficiency virus-associated dementia. Neuropsychiatry Neuropsychol Behav Neurol 12:184–92.
   PubMedGoogle Scholar
• Mintz M (1996). Neurological and developmental problems in pediatric HIV infection. J Nutr 126:2663S–2673S.
   PubMed Web of Science ®Google Scholar
• Mintz M (2005). Clinical features. In: The neurology of AIDS, 2nd ed. Gendelman HE, Grant I, Everall IP, Lipton SA, Swindells S (eds.). New York: Oxford University Press, pp 639–658.
   Google Scholar
• Nagatsu T, Levitt M, Udenfriend S (1964). Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem 239:2910–2917.
   PubMed Web of Science ®Google Scholar
• Reid W, Sadowska M, Denaro F, Rao S, Foulke J Jr, Hayes N, Jones O, Doodnauth D, Davis H, Sill A, O'Driscoll P, Huso D, Fouts T, Lewis G, Hill M, Kamin-Lewis R, Wei C, Ray P, Gallo RC, Reitz M, Bryant J (2001). An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98:9271–9276.
   PubMed Web of Science ®Google Scholar
• Silvers JM, Aksenov MY, Aksenova MV, Beckley J, Olton P, Mactutus CF, Booze RM (2006). Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains. J NeuroVirol 12:140–145.
   PubMed Web of Science ®Google Scholar
• Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2007). Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28:1184–90.
   PubMedGoogle Scholar
• Spear LP (2007). Assessment of adolescent neurotoxicity: rationale and methodological considerations. Neurotoxicol Teratol 29:1–9.
   PubMed Web of Science ®Google Scholar
• Tzschentke TM (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63:241–320.
   PubMed Web of Science ®Google Scholar
• UNAIDS (2008). Report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS. http://data.unaids.org/pub/GlobalReport/2008/JC1510_2008Global Report_en.zip.
   Google Scholar
• Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004). Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127:2452–2458.
   PubMed Web of Science ®Google Scholar
• Webb KM, Mactutus CF, Booze RM (2009). The ART of HIV therapies: dopaminergic deficits and future treatments for HIV pediatric encephalopathy. Expert Rev Anti Infect Ther 7: 93–203
   Google Scholar
• Wolters PL, Brouwers P, Civitello L, Moss HA (1997). Receptive and expressive language function of children with symptomatic HIV infection and relationship with disease parameters: a longitudinal 24-month follow-up study. AIDS 11: 1135–1144.
   PubMed Web of Science ®Google Scholar
• Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M (2000). HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275:4159–4165.
   Google Scholar
• Zhu J, Mactutus CF, Wallace DR, Booze RM (2009). HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329:1071–1083.
   PubMedGoogle Scholar